Realta Holdings, LLC
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jul 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for PIC1 Inhibition of Myeloperoxidase Oxidative Activity in an Animal Model (US 11,712,462) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Peptide Compounds to Regulate the Complement System (US 10,414,799) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Synthetic Peptide Compounds and Methods of Use (US 11,814,414) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,241,843 | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof In force · USPTO record | In force | USPTO record | |
| US 8,906,845 | Peptide Compounds to Regulate the Complement System In force · High confidence | In force | High confidence | |
| US 9,422,337 | Peptide Compounds to Regulate the Complement System In force · High confidence | In force | High confidence | |
| US 9,914,753 | Peptide Compounds to Regulate the Complement System In force · High confidence | In force | High confidence | |
| US 10,005,818 | Derivative peptide compounds and methods of use In force · USPTO record | In force | USPTO record | |
| US 10,414,799 | Peptide Compounds to Regulate the Complement System In force · High confidence | In force | High confidence | |
| US 10,844,093 | Peptide Compounds to Regulate the Complement System In force · High confidence | In force | High confidence | |
| US 10,947,279 | Synthetic Peptide Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,814,414 | Synthetic Peptide Compounds and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 10,933,116 | Synthetic Peptide Compounds and Methods of Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 abandoned · 4 no status recorded